- Patients
- Clinical Research
- Clinical trials
- DREAM3R
2024-06-14T11:33:20.031Z
DREAM3R
DREAM3R
Mesothelia
DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Mesothilial
Study Phase
III
Trial Identifiers
GenesisCare Location(s)
GenesisCare: North Shore PI – Nick Pavlakis
Principal Investigator(s)
Nick Pavlakis